Mursla Bio joins ABHI US Accelerator for EvoLiver rollout

UK–US biotech company Mursla Bio has been selected to join the Association of British HealthTech Industries (ABHI) ABHI US Accelerator, a programme designed to help health technology companies establish and expand their presence in the US healthcare market.

The company plans to use the initiative to support the commercial deployment of EvoLiver, its FDA-designated blood test for liver cancer surveillance, across US health systems, payors and clinical stakeholders.

Participation in the accelerator will provide structured access to more than 300 senior healthcare leaders across 35 hospitals, 20 health systems and US insurers. The programme also offers operational guidance from organisations including Becton Dickinson and Dell Medical School at the University of Texas, as well as ABHI’s US advisor network.

Mursla Bio said the connections are expected to support EvoLiver’s integration into clinical workflows and help translate launch readiness into early adoption among specialist hepatology centres.

Preparing for US launch

The company is continuing preparations for the US introduction of EvoLiver, including CLIA laboratory readiness, engagement with key opinion leaders and clinical societies, and dialogue with payors.

EvoLiver is designed as a blood-based surveillance test for high-risk patients, using hepatocyte-specific extracellular vesicle biology to improve the detection of liver cancer and address limitations associated with standard monitoring approaches.

Liver cancer remains one of the fastest-growing causes of cancer-related mortality in the United States. According to Mursla Bio, challenges in surveillance performance and patient adherence contribute to late diagnosis, creating an opportunity for improved diagnostic tools.

The company said its initial commercial strategy will focus on hepatology-led adoption aligned with clinical guidelines, with broader expansion planned as further clinical evidence supports wider coverage and use.

Building US healthcare connections

Commenting on the announcement, Pierre Arsène, Founder and CEO of Mursla Bio, said:

“Bringing a new test into clinical use depends on reaching the right people across the healthcare system. This programme strengthens those connections while supporting EvoLiver’s early deployment and laying the commercial foundations for our EV diagnostics platform in the US.”

Platform approach to diagnostics

Mursla Bio’s work centres on extracellular vesicle (EV) science and what it describes as a “Dynamic Biopsy” approach. The technology is designed to non-invasively analyse biological processes within a specific organ or tissue by isolating organ-specific EVs from biofluids.

These vesicles are analysed through a multi-omics workflow spanning proteins, miRNAs and mRNAs, supported by an AI-enabled platform for biomarker discovery and assay development.

EvoLiver represents the first clinical application of this approach, with the company initially focused on improving liver cancer surveillance in high-risk populations before expanding into additional precision medicine applications.

Headquartered in Cambridge, UK, with operations in Boston, Massachusetts, Mursla Bio is positioning the US as a key early market for its extracellular vesicle-based diagnostics platform.